1r9m

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 4: Line 4:
==Overview==
==Overview==
-
Dipeptidyl peptidase IV (DPPIV) is a member of the prolyl oligopeptidase, family of serine proteases. DPPIV removes dipeptides from the N terminus, of substrates, including many chemokines, neuropeptides, and peptide, hormones. Specific inhibition of DPPIV is being investigated in human, trials for the treatment of type II diabetes. To understand better the, molecular determinants that underlie enzyme catalysis and substrate, specificity, we report the crystal structures of DPPIV in the free form, and in complex with the first 10 residues of the physiological substrate, Neuropeptide Y (residues 1-10; tNPY). The crystal structure of the free, form of the enzyme reveals two potential channels through which substrates, could access the active site-a so-called propeller opening, and side, opening. The crystal structure of the DPPIV/tNPY complex suggests that, bioactive peptides utilize the side opening unique to DPPIV to access the, active site. Other structural features in the active site such as the, presence of a Glu motif, a well-defined hydrophobic S1 subsite, and, minimal long-range interactions explain the substrate recognition and, binding properties of DPPIV. Moreover, in the DPPIV/tNPY complex, structure, the peptide is not cleaved but trapped in a tetrahedral, intermediate that occurs during catalysis. Conformational changes of S630, and H740 between DPPIV in its free form and in complex with tNPY were, observed and contribute to the stabilization of the tetrahedral, intermediate. Our results facilitate the design of potent, selective small, molecule inhibitors of DPPIV that may yield compounds for the development, of novel drugs to treat type II diabetes.
+
Dipeptidyl peptidase IV (DPPIV) is a member of the prolyl oligopeptidase family of serine proteases. DPPIV removes dipeptides from the N terminus of substrates, including many chemokines, neuropeptides, and peptide hormones. Specific inhibition of DPPIV is being investigated in human trials for the treatment of type II diabetes. To understand better the molecular determinants that underlie enzyme catalysis and substrate specificity, we report the crystal structures of DPPIV in the free form and in complex with the first 10 residues of the physiological substrate, Neuropeptide Y (residues 1-10; tNPY). The crystal structure of the free form of the enzyme reveals two potential channels through which substrates could access the active site-a so-called propeller opening, and side opening. The crystal structure of the DPPIV/tNPY complex suggests that bioactive peptides utilize the side opening unique to DPPIV to access the active site. Other structural features in the active site such as the presence of a Glu motif, a well-defined hydrophobic S1 subsite, and minimal long-range interactions explain the substrate recognition and binding properties of DPPIV. Moreover, in the DPPIV/tNPY complex structure, the peptide is not cleaved but trapped in a tetrahedral intermediate that occurs during catalysis. Conformational changes of S630 and H740 between DPPIV in its free form and in complex with tNPY were observed and contribute to the stabilization of the tetrahedral intermediate. Our results facilitate the design of potent, selective small molecule inhibitors of DPPIV that may yield compounds for the development of novel drugs to treat type II diabetes.
==About this Structure==
==About this Structure==
Line 16: Line 16:
[[Category: Aertgeerts, K.]]
[[Category: Aertgeerts, K.]]
[[Category: Collins, B.]]
[[Category: Collins, B.]]
-
[[Category: Prasad, G.S.]]
+
[[Category: Prasad, G S.]]
[[Category: Rogers, J.]]
[[Category: Rogers, J.]]
-
[[Category: Sang, B.C.]]
+
[[Category: Sang, B C.]]
-
[[Category: Skene, R.J.]]
+
[[Category: Skene, R J.]]
-
[[Category: Tennant, M.G.]]
+
[[Category: Tennant, M G.]]
-
[[Category: Webb, D.R.]]
+
[[Category: Webb, D R.]]
[[Category: Ye, S.]]
[[Category: Ye, S.]]
[[Category: FUC]]
[[Category: FUC]]
Line 29: Line 29:
[[Category: serine protease]]
[[Category: serine protease]]
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri Feb 15 16:47:59 2008''
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 14:48:28 2008''

Revision as of 12:48, 21 February 2008


1r9m, resolution 2.10Å

Drag the structure with the mouse to rotate

Crystal Structure of Human Dipeptidyl Peptidase IV at 2.1 Ang. Resolution.

Overview

Dipeptidyl peptidase IV (DPPIV) is a member of the prolyl oligopeptidase family of serine proteases. DPPIV removes dipeptides from the N terminus of substrates, including many chemokines, neuropeptides, and peptide hormones. Specific inhibition of DPPIV is being investigated in human trials for the treatment of type II diabetes. To understand better the molecular determinants that underlie enzyme catalysis and substrate specificity, we report the crystal structures of DPPIV in the free form and in complex with the first 10 residues of the physiological substrate, Neuropeptide Y (residues 1-10; tNPY). The crystal structure of the free form of the enzyme reveals two potential channels through which substrates could access the active site-a so-called propeller opening, and side opening. The crystal structure of the DPPIV/tNPY complex suggests that bioactive peptides utilize the side opening unique to DPPIV to access the active site. Other structural features in the active site such as the presence of a Glu motif, a well-defined hydrophobic S1 subsite, and minimal long-range interactions explain the substrate recognition and binding properties of DPPIV. Moreover, in the DPPIV/tNPY complex structure, the peptide is not cleaved but trapped in a tetrahedral intermediate that occurs during catalysis. Conformational changes of S630 and H740 between DPPIV in its free form and in complex with tNPY were observed and contribute to the stabilization of the tetrahedral intermediate. Our results facilitate the design of potent, selective small molecule inhibitors of DPPIV that may yield compounds for the development of novel drugs to treat type II diabetes.

About this Structure

1R9M is a Single protein structure of sequence from Homo sapiens with and as ligands. Active as Dipeptidyl-peptidase IV, with EC number 3.4.14.5 Full crystallographic information is available from OCA.

Reference

Crystal structure of human dipeptidyl peptidase IV in complex with a decapeptide reveals details on substrate specificity and tetrahedral intermediate formation., Aertgeerts K, Ye S, Tennant MG, Kraus ML, Rogers J, Sang BC, Skene RJ, Webb DR, Prasad GS, Protein Sci. 2004 Feb;13(2):412-21. Epub 2004 Jan 10. PMID:14718659

Page seeded by OCA on Thu Feb 21 14:48:28 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools